Head & Neck Squamous Cell Carcinoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Nivolumab Plus Ipilimumab Fails to Overcome Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma

09/02/2026

Viktor Grünwald, MD, PhD

Viktor Grünwald, MD, PhD, discusses results from the phase 2 OPTIM study evaluating nivolumab plus ipilimumab versus docetaxel after failure to respond to nivolumab in head and neck cancer, highlighting the need for novel strategies to...

Viktor Grünwald, MD, PhD,...

09/02/2026

Oncology

Videos

Statin-Specific Effects May Influence Immunotherapy Outcomes in Patients With Head and Neck Squamous Cell Carcinoma

09/02/2026

Allen Khudaverdyan, MD

Allen Khudaverdyan, MD, discusses results from a large retrospective study evaluating concurrent statin use in patients with head and neck squamous cell carcinoma receiving immune checkpoint inhibitors, highlighting statin-specific survival...

Allen Khudaverdyan, MD,...

09/02/2026

Oncology

Videos

Perioperative Pembrolizumab May Not Be Cost-Effective in Advanced Head and Neck Cancer

09/02/2026

Christopher Noel, MD, PhD

Christopher Noel, MD, PhD, discusses a cost-effectiveness analysis of perioperative pembrolizumab in locally advanced head and neck cancer, highlighting how current drug pricing and treatment duration may limit cost-effectiveness despite the...

Christopher Noel, MD, PhD,...

09/02/2026

Oncology

Videos

Subcutaneous Amivantamab Shows Promise in Previously Treated HPV-Negative Head and Neck Cancer

08/06/2026

Barbara Burtness, MD, FASCO

Barbara Burtness, MD, discusses results from cohort 1 of the phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in previously treated HPV-negative head and neck squamous cell carcinoma, highlighting encouraging response rates,...

Barbara Burtness, MD, discusses...

08/06/2026

Oncology

Videos

Early-Phase Immunotherapy Demonstrates Modest Activity in Recurrent or Metastatic Head and Neck Cancer

07/28/2026

Harold Nathan Tan, MD

Harold Nathan Tan, MD, discusses findings from a retrospective analysis of early-phase immunotherapy trials in recurrent or metastatic head and neck squamous cell carcinoma, highlighting the clinical activity of bispecific antibodies and the...

Harold Nathan Tan, MD, discusses...

07/28/2026

Oncology

Videos

FID-007 Plus Cetuximab Demonstrates Encouraging Activity in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

06/05/2026

Guilherme Rabinowits, MD

Guilherme Rabinowits, MD, discusses results from a phase 2 trial which demonstrated that FID-007 plus cetuximab showed promising activity and manageable safety in patients with recurrent or metastatic head and neck squamous cell carcinoma who...

Guilherme Rabinowits, MD,...

06/05/2026

Oncology

Videos

ASP-1929 Photoimmunotherapy Demonstrates Clinical Benefit in Recurrent Head and Neck Squamous Cell Carcinoma

06/05/2026

Anastasios Maniakas, MD, PhD

Anastasios Maniakas, MD, PhD, discusses results from a phase 3 study which found that ASP-1929 photoimmunotherapy improved response and quality-of-life outcomes in recurrent head and neck squamous cell carcinoma.

Anastasios Maniakas, MD, PhD,...

06/05/2026

Oncology

Videos

Amivantamab Demonstrates Durable Responses in HPV-Unrelated Head and Neck Squamous Cell Carcinoma

06/05/2026

Barbara Burtness, MD, FASCO

Barbara Burtness, MD, FASCO, discusses phase 2 OrigAMI-4 results showing that subcutaneous amivantamab achieved a 47% response rate in HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma after progression on...

Barbara Burtness, MD, FASCO,...

06/05/2026

Oncology

Videos

Emi-Le Demonstrates Promising Activity in Aggressive Adenoid Cystic Carcinoma

06/01/2026

Glenn Hanna, MD

Glenn Hanna, MD, discusses promising phase 1 results for emiltatug ledadotin (Emi-Le; XMT-1660), a novel B7-H4-directed antibody-drug conjugate that demonstrated encouraging efficacy and a favorable safety profile in patients with aggressive...

Glenn Hanna, MD, discusses...

06/01/2026

Oncology

Videos

Metabolic Subtyping Predicts Immunotherapy Response in Nasopharyngeal Carcinoma

05/13/2026

Sai-Wei Huang, MD

Sai-Wei Huang, MD, discusses findings from a study evaluating metabolic biomarkers in patients with nasopharyngeal carcinoma using RNA sequencing.

Sai-Wei Huang, MD, discusses...

05/13/2026

Oncology

Recent News

FDA Approval

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

09/18/2026

Stephanie Holland

Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...

Based on results from the phase...

09/18/2026

Oncology

FDA Alerts

FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer

09/17/2026

Emily Estrada

The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...

The FDA approved a supplemental...

09/17/2026

Oncology

News

Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma

09/17/2026

Emily Estrada

Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...

Results from the phase 3 EPCORE...

09/17/2026

Oncology

News

Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation

09/17/2026

Emily Estrada

Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...

Results from a phase 3 trial...

09/17/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer

09/16/2026

Stephanie Holland

Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...

Results from the phase 3...

09/16/2026

Oncology

FDA Alerts

FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access

09/16/2026

Stephanie Holland

The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...

The FDA updated the prescribing...

09/16/2026

Oncology

News

Tarlatamab Plus Durvalumab Improves Survival as First-Line Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

09/15/2026

Emily Estrada

Topline results from the phase 3 DeLLphi-305 trial showed that adding tarlatamab to durvalumab significantly improved overall and progression-free survival compared with durvalumab alone as first-line maintenance therapy for patients with...

Topline results from the phase 3...

09/15/2026

Oncology

News

GLP-1 Receptor Agonists Linked to Lower Mortality and Thrombotic Complications in Essential Thrombocythemia

09/15/2026

Emily Estrada

Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...

Real-world findings associated...

09/15/2026

Oncology

News

Sustained Ropeginterferon Alfa-2b Treatment Deepens Molecular Responses in High-Risk Essential Thrombocythemia

09/15/2026

Emily Estrada

Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...

Extended results from the phase...

09/15/2026

Oncology

News

Ropeginterferon Alfa-2b Achieves Increasing Complete Hematologic Response Rates With Longer Treatment in Patients With Myeloproliferative Neoplasms

09/15/2026

Emily Estrada

Results from a real-world study demonstrated that ropeginterferon alfa-2b produced increasing complete hematologic responses over time in patients with myeloproliferative neoplasms, including essential thrombocythemia, with tolerability...

Results from a real-world study...

09/15/2026

Oncology